[1] Dornhorst A. Insulinotropic meglitinide analogues. Lancet. 2001; 358: 1709-1716.
[2] Hatorp V. Clinical pharmacokinetics and pharmacodynamics of repaglinide. Clin Pharmacokinet. 2002; 41(7): 471-483.
[3] Culy CR, Jarvis B. Repaglinide: a review of its therapeutic use in treatment of type 2 diabetes mellitus. Drugs. 2001; 61(11): 1625-1660.
[4] Bidstrup TB, Bjornsdottir I, Sidelmann UG, Thamsen MS, Hansen KT. CYP2C8 and CYP3A4 are the principal enzymes involved in the human in vitro biotransformation of the insulin secretagogue repaglinide. British J Clin Pharmacol. 2003; 56(3): 301-314.
[5] Rendic S, Carlo FJ. Human cytochrome P450 enzyme: a status report summarizing their reaction, substrates, inducers and inhibitors. Drug Met Rev. 1997; 29: 413-580.
[6] Dai D, Darryl C, Zeldin DC, Blasidell JA, Chanas B, Coulter SJ, et al. Polymorphisms in human CYP2C8 decrease metabolism of the anticancer drug paclitaxel and arachidonic acid. Pharmacogenetics. 2001; 11(7): 597- 607.
[7] Yamazaki H, Shibata A, Suzuki M, Nakajima M, Shimada N, Guengerich FP. Oxidation of troglitazone to a quinine-type metabolite catalyzed by cytocrome P450 2C8 and P450 3A4 in human liver microsomes. Drug Metab Dispos. 1999; 27: 1260-1266.
[8] Muck W. Clinical pharmacokinetics of cerivastatin. Clin Pharmacokinet. 2000; 39: 99-116.
[9] Shimada T, Yamazaki H, Mimura M, Inui Y, Guengerich FP. Interindividual variations in human liver cytochrome P450 enzymes involved in the oxidation of drugs, carcinogens and toxic chemicals. J Pharmacol Exp Therap. 1994; 270: 414-423.
[10] Watkins PB. Non-invasive tests of CYP3A4 enzymes. Pharmacogenetics. 1994; 4: 171-184.
[11] Hamilton J, Parry B. Sex-related differences in clinical drug response: Implications for women’s health. J American Med Womens Assoc. 1983; 38:126-132.
[12] Yee GC, Lennon TP, Gmur DJ. Age-dependent cyclosporine: pharmacokinetics in marrow transplant recipients. Clin Pharmacol Therap. 1986; 40: 438-443.
[13] Greenbalt DJ, Harmatz JS, von Moltke LL. Age and gender effects on the pharmacokinetics and pharmacodynamics of triazolam, a cytochrome P450 3A substrate. Clin Pharmacol Therap. 2004; 76: 467-479.
[14] Krecic-Shepard ME, Barnas CR, Slimko J, Schwartz JB. Faster clearance of sustained release verapamil in men versus women: continuing observations on sex-specific defferencesafter oral administration of verapamil. Clin Pharmacol Therap. 2000; 68: 286-92.
[15] Ruzilawati AB, Suhaimi AW, Imran A, Ismail Z, Gan SH. Method development and validation of repaglinide in human plasma by HPLC and its application to pharmacokinetics study. J Pharm Biomed Anal. 2007; 43(5): 1831-1835.
[16] Ruzilawati AB, Mohd Suhaimi AW, Gan SH. Genetic polymorphisms of CYP3A4: CYP3A4*18 allele is found in five healthy Malaysian subjects, Clin Chim Acta. 2007; 383: 158-162.
[17] Muthiah YD, Lee WL, Teh LK, Ong CE, Salleh MZ, Ismail R. A simple multiplex PCR method for the concurrent detection of three CYP2C8 variants. Clin Chim Acta. 2004; 349: 191-198.
[18] Ruzilawati AB, Mohd Suhaimi AW, Gan SH. Population pharmacokinetic modeling of repaglinide in healthy subjects by using nonparametric adaptive grid (NPAG) algorithm. J Clin Pharm Therap. 2010; 35: 105-112.
[19] Meibohm B, Beierle I, Derendorf H. How important are gender differences in pharmacokinetics? Clin Pharmacokinet. 2002; 41 (5): 329-342.
[20] Haidar SH, Johnson SB, Fossler MJ, Hussain AS. Modeling the pharmacokinetics and pharmacodynamics of a unique oral hypoglycemic agent using neural networks. Pharm Res. 2002; 19(1): 87-91.
[21] Harris RZ, Benet LZ, Schwartz JB. Gender effects in pharmacokinetics and pharmacodynamics. Drugs. 1995; 50: 222-239.
[22] Hutson WR, Roehrkasse RL, Wald A. Influence of gender and menopause on gastric emptying and motility. Gastroenterology. 1989; 96: 617-629.
[23] Abad-Santos F, Novalbos J, Galvez-Mugica MA, Gallego-Sandin S, Almeida S, Vallee F. Assessment of sex differences in pharmacokinetics and pharmacodynamics of amlodipine in a bioequivalence study. Pharm Res. 2005; 51: 445-452.
[24] Franconi F, Brunelleschi S, Steardo L et al. Gender differences in drug responses. Pharm Res. 2007; 55: 81-95.
[25] Greenblatt DJ, Divoll M, Abernethy DR. Physiologic changes in old age: Relation to altered drug disposition. J Am Geriatr Soc. 1982; 30(Suppl): S6–S10.
[26] Chen M, Ma L, Drunsano GL, Nafziger AN. Sex differences in CYP3A4 activity using intravenous and oral midazolam. Clin Pharmacol Therap. 2006; 80: 531-538.
[27] Schmucker DL, Woodhouse KW, Wang RK, Wyne H, James OH, McManus M. Effects of age and gender on in vitro properties of human liver microsomal mono-oxygenase. Clin Pharmacol Therap. 1990; 48: 365-374.
[28] He P, Court MH, Greenblatt DJ, von-Moltke LL. Genotype-phenotype associations of cytochrome P450 3A4 and 3A5 polymorphism with midazolam clearance in vivo. Clin Pharmacol Therap. 2005; 77: 373-387.
[29] Wolbold R, Klein K, Burk O, Nussler AK, Neuhaus P, Eichelbaum M. Sex is a major determinant of CYP3A4 expression in human liver. Hepatology. 2003; 38: 978- 988.
[30] Tanaka E. Gender-related differences in pharmacokinetics and their clinical significance. J Clini Pharm Therap. 1999; 24: 339-346.
[31] Kivisto KT, Kroemer HK. Use of probe drugs as predictors of drug metabolism in humans. J Clin Pharmacol. 1997; 37 (Suppl.): 40S-48S.